Table 5 Estimated costs in treatment-naïve HCV patients and matched controls
From: The burden of hepatitis C in Europe from the patients’ perspective: a survey in 5 countries
HCV Never treated | Matched controls | p-value | |||
|---|---|---|---|---|---|
(n = 139) | (n = 139) | ||||
M | SD | M | SD | ||
Indirect costs | |||||
Absenteeism | € 1,293.61 | € 4,398.13 | € 579.62 | € 2,504.32 | .204 |
Presenteeism | € 5,120.80 | € 7,680.29 | € 3,062.29 | € 5,868.47 | .015 |
Total indirect | € 6,414.42 | € 8,587.96 | € 3,641.91 | € 6,699.54 | .011 |
Direct costs | |||||
Physician visits | € 488.06 | € 720.02 | € 288.44 | € 458.58 | .003 |
ER visits | € 47.18 | € 178.64 | € 39.19 | € 140.43 | .979 |
Hospitalizations | € 399.05 | € 1,368.76 | € 179.88 | € 858.29 | .124 |
Total direct | € 934.30 | € 1,873.33 | € 507.50 | € 1,053.43 | .005 |
Total costs | € 3,834.44 | € 6,991.25 | € 2,119.56 | € 4,974.79 | <.001 |